Shots: The approval follows the REWIND study which involves assessing of Trulicity + SoC (1.5mg) vs PBO + SoC in adults with T2D The study showed reduction in MACE events […]readmore
Tags : MACE
Shots: The approval is based on SUSTAIN 6 CVOT study assessing Ozempic (0.5mg /1mg, inj.) vs PBO + SOC in 3297 patients with T2D with established CVDs The SUSTAIN 6 […]readmore
Shots: Results of P-III ODYSSEY OUTCOMES assessing PRALUENT(alirocumab) IV (N= 18,924), having an acute coronary syndrome (ACS), such as a heart attack, b/w 1-12 mos before being enrolled The US […]readmore